MYC in Oncogenesis and Therapeutic Implications

Abstract

The MYC oncogene family constitutes a master regulatory hub in tumorigenesis, with functional complexity extending far beyond individual gene activities. Recent advances unveil cooperative yet context-dependent antagonism and dynamic interplay among MYC family members, fundamentally reshaping our understanding of lineage specific oncogenic programs. This review synthesizes emerging insights into MYC orchestrated tumor microenvironment remodeling, reciprocal regulation with noncoding RNAs, and the transcriptional and epigenetic governance of metabolic reprogramming. We delineate mechanisms by which MYC drives therapeutic resistance and critically evaluate current strategies targeting MYC or its downstream networks, encompassing direct MYC–MAX disruptors, upstream pathway inhibitors, synthetic lethality, and combinatorial regimens with immune checkpoint blockade or conventional chemotherapy. We further discuss MYC's prognostic significance across diverse cancer types, the critical gap between preclinical efficacy and clinical outcomes, and emerging combination strategies aimed at overcoming acquired drug resistance. By integrating these rapidly evolving biological dimensions, we posit MYC as a highly multidimensional regulatory node whose context-dependent functions present both formidable challenges and promising new opportunities for effective therapeutic intervention.

Keywords

clinical trials / indirect targeting / mechanism / myc oncogene / therapeutic targets

References

[1] Z. Deng and D. R. Richardson, “The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions With Innovative Therapeutics,” Pharmacological Reviews 75, no. 5 (2023): 1007–1035.

[2] Y. Han, C. Mao, K. Zhou, et al., “Fragile X Mental Retardation 1 Gene FMR1 Promotes Proliferation, Migration, and Invasion of Gastric Cancer Cells via c-MYC,” Journal of Translational Medicine 23, no. 1 (2025): 1210.

[3] E. E. Gardner, E. M. Earlie, K. Li, et al., “Lineage-Specific Intolerance to Oncogenic Drivers Restricts Histological Transformation,” Science 383, no. 6683 (2024): eadj1415.

[4] S. Panja, M. I. Truica, C. Y. Yu, et al., “Mechanism-Centric Regulatory Network Identifies NME2 and MYC Programs as Markers of Enzalutamide Resistance in CRPC,” Nature Communications 15, no. 1 (2024): 352.

[5] J. Fang, J. Fang, S. Singh, et al., “The Context-Dependent Epigenetic and Organogenesis Programs Determine 3D vs. 2D Cellular Fitness of MYC-Driven Murine Liver Cancer Cells,” eLife 14 (2025): RP101299.

[6] Y. Zhu, Y. Gao, X. Huang, et al., “Pan-Cancer Analysis Reveals TRA16 as a Master Regulator of Human Carcinogenesis,” Frontiers in Oncology 15 (2025): 1543419.

[7] L. V. Subramanyan, S. A. K. Rasheed, L. Wang, et al., “GNA13 Suppresses Proliferation of ER+ Breast Cancer Cells via ERalpha Dependent Upregulation of the MYC Oncogene,” Breast Cancer Research 26 (2024): 113.

[8] S. Chakraborty, M. Balan, A. Sabarwal, T. K. Choueiri, and S. Pal, “Metabolic Reprogramming in Renal Cancer: Events of a Metabolic Disease,” Biochimica et Biophysica Acta – Reviews on Cancer 1876, no. 1 (2021): 188559.

[9] Q. Luo, F. Shen, S. Zhao, et al., “LINC00460/miR-186-3p/MYC Feedback Loop Facilitates Colorectal Cancer Immune Escape by Enhancing CD47 and PD-L1 Expressions,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 225.

[10] J. Ding, M. Bansal, Y. Cao, et al., “MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress During Cancer Development,” Cancer Research 84 (2024): 4031–4048.

[11] V. Llombart and M. R. Mansour, “Therapeutic Targeting of “Undruggable” MYC,” eBioMedicine 75 (2022): 103756.

[12] S. Choi, S. P. Hong, J. H. Bae, et al., “Hyperactivation of YAP/TAZ Drives Alterations in Mesangial Cells Through Stabilization of N-Myc in Diabetic Nephropathy,” Journal of the American Society of Nephrology 34, no. 5 (2023): 809–828.

[13] Y. Nishida, J. Ishizawa, E. Ayoub, et al., “Enhanced TP53 Reactivation Disrupts MYC Transcriptional Program and Overcomes Venetoclax Resistance in Acute Myeloid Leukemias,” Science Advances 9, no. 48 (2023): eadh1436.

[14] D. Pradella, M. Zhang, R. Gao, et al., “Engineered Extrachromosomal Oncogene Amplifications Promote Tumorigenesis,” Nature 637, no. 8047 (2025): 955–964.

[15] G. R. Bhat, I. Sethi, H. Q. Sadida, et al., “Cancer Cell Plasticity: From Cellular, Molecular, and Genetic Mechanisms to Tumor Heterogeneity and Drug Resistance,” Cancer and Metastasis Reviews 43 (2024): 197–228.

[16] Z. D. Shi, K. Pang, Z. X. Wu, et al., “Tumor Cell Plasticity in Targeted Therapy-Induced Resistance: Mechanisms and New Strategies,” Signal Transduction and Targeted Therapy 8 (2023): 113.

[17] N. Bou Antoun and A. M. Chioni, “Dysregulated Signalling Pathways Driving Anticancer Drug Resistance,” International Journal of Molecular Sciences 24 (2023): 12222.

[18] N. Karadkhelkar and K. D. Janda, “Demystifying the Druggability of the MYC Family of Oncogenes,” Journal of the American Chemical Society 145 (2023): 3259–3269.

[19] J. Chou, M. Kaller, S. Jaeckel, M. Rokavec, and H. Hermeking, “AP4 Suppresses DNA Damage, Chromosomal Instability and Senescence via Inducing MDC1/Mediator of DNA Damage Checkpoint 1 and Repressing MIR22HG/miR-22-3p,” Molecular Cancer 21, no. 1 (2022): 120.

[20] R. K. Jha, F. Kouzine, and D. Levens, “MYC Function and Regulation in Physiological Perspective,” Frontiers in Cell and Developmental Biology 11 (2023): 1268275.

[21] X. Lai, H. Yoda, Y. Qiao, et al., “ATR Inhibition Synergizes With Alkylating PI Polyamide Targeting N-MYC by Suppressing DNA Repair in N-MYC-Amplified Neuroblastoma,” Cancer Science 116 (2025): 1691–1702.

[22] J. Tang, R. Moorthy, L. E. Hirsch, et al., “Targeting N-Myc in Neuroblastoma With Selective Aurora Kinase A Degraders,” Cell Chemical Biology 32, no. 2 (2025): 352–362.e10.

[23] M. Xu, H. Shi, Y. Shen, et al., “Diminished MYCN Dosage Endows Cavitary Transformation in Retinoblastoma,” Ophthalmology Science 5, no. 5 (2025): 100820.

[24] J. R. Whitfield and L. Soucek, “MYC in Cancer: From Undruggable Target to Clinical Trials,” Nature Reviews Drug Discovery 24 (2025): 445–457.

[25] L. Ding, W. Ni, Y. Ma, et al., “PDCD11 Stabilizes C-MYC Oncoprotein by Hindering C-MYC-SKP2 Negative Feedback Loop to Facilitate Progression of p53-Mutant Breast and Colon Malignancies,” Advanced Science 12, no. 17 (2025): e2502416.

[26] N. Zielke, A. Vähärautio, J. Liu, T. Kivioja, and J. Taipale, “Upregulation of Ribosome Biogenesis via Canonical E-Boxes Is Required for Myc-Driven Proliferation,” Developmental Cell 57, no. 8 (2022): 1024–1036.e5.

[27] D. A. Anderson, F. Ou, S. Kim, T. L. Murphy, and K. M. Murphy, “Transition From cMyc to L-Myc During Dendritic Cell Development Coordinated by Rising Levels of IRF8,” Journal of Experimental Medicine 219, no. 2 (2022): e20211483.

[28] H. Wang, X. Wu, J. Gao, et al., “Targeting Myc Through BET-PROTAC Elicits Potent Anti-Lymphoma Activity in Diffuse Large B Cell Lymphoma,” Investigational New Drugs 43, no. 3 (2025): 621–633.

[29] A. K. Michael, L. Stoos, P. Crosby, et al., “Cooperation Between bHLH Transcription Factors and Histones for DNA Access,” Nature 619 (2023): 385–393.

[30] Z. Xia, M. Tang, J. Ma, et al., “Epitranscriptomic Editing of the RNA N6-Methyladenosine Modification by dCasRx Conjugated Methyltransferase and Demethylase,” Nucleic Acids Research 49, no. 13 (2021): 7361–7374.

[31] Y. Zeng, H. Jiang, X. Zhang, et al., “Canagliflozin Reduces Chemoresistance in Hepatocellular Carcinoma Through PKM2-c-MYC Complex-Mediated Glutamine Starvation,” Free Radical Biology and Medicine 208 (2023): 571–586.

[32] X. Li, Z. Zhang, F. Gao, et al., “c-MYC-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer,” Journal of the American Chemical Society 145, no. 16 (2023): 9334–9342.

[33] L. Y. D. Johnson, I. T. Major, Y. Chen, C. Yang, L. J. Vanegas-Cano, and G. A. Howe, “Diversification of JAZ-MYC Signaling Function in Immune Metabolism,” New Phytologist 239, no. 6 (2023): 2277–2291.

[34] K. H. Ho, K. F. Pan, T. Y. Cheng, M. H. Chien, and K. T. Hua, “Multiple Impacts of Naa10p on Cancer Progression: Molecular Functions and Clinical Prospects,” Biochimica et Biophysica Acta – Reviews on Cancer 1878, no. 6 (2023): 188973.

[35] S. Nagel, C. Pommerenke, C. Meyer, M. Kaufmann, and R. A. F. MacLeod, “Chromosomal Aberration T(14;17)(q32;q21) Simultaneously Activates HOXB5 and miR10a in Triple-Hit B-Cell Lymphoma,” Biomedicines 11, no. 6 (2023): 1758.

[36] N. Joshi, K. M. Dunleavy, K. M. Beel, et al., “Aurora A Binds to the Transactivation Domain of C-MYC and Recognizes the Phosphorylated N-Terminal Degron Motif,” Biochemical Journal 482 (2025): 369–381.

[37] S. R. Boyd, S. Chamakuri, A. J. Trostle, et al., “MYC-Targeting PROTACs Lead to Bimodal Degradation and N-Terminal Truncation,” ACS Chemical Biology 20 (2025): 896–906.

[38] T. Sen, N. Takahashi, S. Chakraborty, et al., “Emerging Advances in Defining the Molecular and Therapeutic Landscape of Small-Cell Lung Cancer,” Nature Reviews Clinical Oncology 21, no. 8 (2024): 610–627.

[39] R. El Baba, S. Pasquereau, and S. Haidar Ahmad, “EZH2-Myc Driven Glioblastoma Elicited by Cytomegalovirus Infection of Human Astrocytes,” Oncogene 42, no. 24 (2023): 2031–2045.

[40] S. Satpathy, K. Krug, and P. M. Jean Beltran, “A Proteogenomic Portrait of Lung Squamous Cell Carcinoma,” Cell 184, no. 16 (2021): 4348–4371.e40.

[41] M. Yegambaram, X. Sun, Q. Lu, et al., “c-MYC Promotes Metabolic Reprogramming in Pulmonary Hypertension via the Stimulation of Glutaminolysis and the Reductive Tricarboxylic Acid Cycle,” Redox Biology 85 (2025): 103765.

[42] J. Zhang, Y. Jin, and H. Lin, “Amplification of Extrachromosomal MYC Paralogs Shapes Immunosuppressive Tumor Microenvironment in Small Cell Lung Cancer,” Clinical Cancer Research 31, no. 21 (2025): 4529–4542.

[43] Z. O. Doha, X. Wang, N. L. Calistri, et al., “MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer,” Nature Communications 14 (2023): 5665.

[44] S. Qu, P. Fetsch, A. Thomas, et al., “Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers,” Journal of Thoracic Oncology 17, no. 1 (2022): 141–153.

[45] S. Fuchs, C. Danßmann, F. Klironomos, et al., “Defining the Landscape of Circular RNAs in Neuroblastoma Unveils a Global Suppressive Function of MYCN,” Nature Communications 14, no. 1 (2023): 3936.

[46] C. Cheng, T. He, K. Chen, et al., “P300 Interacted With N-Myc and Regulated Its Protein Stability via Altering Its Post-Translational Modifications in Neuroblastoma,” Molecular & Cellular Proteomics 22 (2023): 100504.

[47] S. K. Das, B. A. Lewis, and D. Levens, “MYC: A Complex Problem,” Trends in Cell Biology 33 (2023): 235–246.

[48] P. Lin, C. Lourenco, J. Cruickshank, et al., “Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality,” Cancer Research 83, no. 24 (2023): 4015–4029.

[49] K. L. Simpson, D. G. Rothwell, F. Blackhall, and C. Dive, “Challenges of Small Cell Lung Cancer Heterogeneity and Phenotypic Plasticity,” Nature Reviews Cancer 25, no. 6 (2025): 447–462.

[50] Z. Li, Z. Yang, W. Liu, et al., “Disheveled3 Enhanced EMT and Cancer Stem-Like Cells Properties via Wnt/Beta- Catenin/C-MYC/SOX2 Pathway in Colorectal Cancer,” Journal of Translational Medicine 21 (2023): 302.

[51] N. T. B. Nguyen, S. Gevers, R. N. U. Kok, et al., “Lactate Controls Cancer Stemness and Plasticity Through Epigenetic Regulation,” Cell Metabolism 37, no. 4 (2025): 903–919.e10.

[52] S. Xiang, P. Chen, X. Shi, et al., “Disruption of the KLHL37-N-Myc Complex Restores N-Myc Degradation and Arrests Neuroblastoma Growth in Mouse Models,” Journal of Clinical Investigation 135, no. 14 (2025): e176655.

[53] S. Chakraborty, C. Coleman, P. Manoj, et al., “De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways,” Clinical Cancer Research 29 (2023): 3526–3540.

[54] X. Zhang, X. Cong, and X. Jin, “Deficiency of BAP1 Inhibits Neuroblastoma Tumorigenesis Through Destabilization of MYCN,” Cell Death & Disease 14, no. 8 (2023): 504.

[55] B. Deng, B. Ke, Q. Tian, Y. Gao, Q. Zhai, and W. Zhang, “Targeting AURKA With Multifunctional Nanoparticles in CRPC Therapy,” Journal of Nanobiotechnology 22, no. 1 (2024): 803.

[56] W. Fiskus, C. P. Mill, P. Bose, et al., “Preclinical Efficacy of CDK7 Inhibitor-Based Combinations Against Myeloproliferative Neoplasms Transformed to AML,” Blood 145, no. 6 (2025): 612–624.

[57] M. J. Duffy, M. Tang, and J. Crown, “MYC as a Target for Cancer Treatment: From Undruggable to Druggable?,” Targeted Oncology 20, no. 5 (2025): 791–801.

[58] Y. Zhao, Z. X. Li, Y. J. Zhu, et al., “Single-Cell Transcriptome Analysis Uncovers Intratumoral Heterogeneity and Underlying Mechanisms for Drug Resistance in Hepatobiliary Tumor Organoids,” Advanced Science 8, no. 11 (2021): e2003897.

[59] J. Yang, F. Chen, L. Lang, et al., “Therapeutic Targeting of the GLS1-c-MYC Positive Feedback Loop Suppresses Glutaminolysis and Inhibits Progression of Head and Neck Cancer,” Cancer Research 84, no. 19 (2024): 3223–3234.

[60] L. N. Davis, Z. J. Walker, L. T. Reiman, et al., “MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance,” Clinical Cancer Research 30, no. 14 (2024): 3023–3035.

[61] W. Yang, Q. Guo, S. Quan, et al., “Impaired Mitochondrial Metabolism Is a Critical Cancer Vulnerability for MYC Inhibitors,” Science Advances 11, no. 29 (2025): eadw5228.

[62] C. Zhang, L. Zhou, M. Zhang, et al., “H3K18 Lactylation Potentiates Immune Escape of Non-Small Cell Lung Cancer,” Cancer Research 84, no. 21 (2024): 3589–3601.

[63] V. Tambay, V. A. Raymond, and M. Bilodeau, “MYC Rules: Leading Glutamine Metabolism Toward a Distinct Cancer Cell Phenotype,” Cancers 13, no. 17 (2021): 4484.

[64] R. Dhanasekaran, A. Deutzmann, W. D. Mahauad-Fernandez, A. S. Hansen, A. M. Gouw, and D. W. Felsher, “The MYC Oncogene—The Grand Orchestrator of Cancer Growth and Immune Evasion,” Nature Reviews Clinical Oncology 19, no. 1 (2022): 23–36.

[65] Y. Teng, C. Luo, X. Qiu, et al., “Plant-Nanoparticles Enhance Anti-PD-L1 Efficacy by Shaping Human Commensal Microbiota Metabolites,” Nature Communications 16, no. 1 (2025): 1295.

[66] Y. Duan, Z. Liu, Q. Wang, et al., “Targeting MYC: Multidimensional Regulation and Therapeutic Strategies in Oncology,” Genes & Diseases 12 (2025): 101435.

[67] O. V. Anatskaya and A. E. Vinogradov, “Polyploidy and Myc Proto-Oncogenes Promote Stress Adaptation via Epigenetic Plasticity and Gene Regulatory Network Rewiring,” International Journal of Molecular Sciences 23 (2022): 9691.

[68] D. Belenki, P. Richter-Pechanska, Z. Shao, et al., “Senescence-Associated Lineage-Aberrant Plasticity Evokes T-Cell-Mediated Tumor Control,” Nature Communications 16 (2025): 3079.

[69] Y. Yao, J. F. Ng, W. D. Park, et al., “CDK7 Controls E2F- and MYC-Driven Proliferative and Metabolic Vulnerabilities in Multiple Myeloma,” Blood 141 (2023): 2841–2852.

[70] M. D. Thakur, C. J. Franz, L. Brennan, et al., “Immune Contexture of Paediatric Cancers,” European Journal of Cancer 170 (2022): 179–193.

[71] D. K. H. Thng, T. B. Toh, P. Pigini, et al., “Splice-Switch Oligonucleotide-Based Combinatorial Platform Prioritizes Synthetic Lethal Targets CHK1 and BRD4 Against MYC-Driven Hepatocellular Carcinoma,” Bioengineering & Translational Medicine 8 (2023): e10363.

[72] R. M. Chabanon and S. P. Vinay, “A Novel Synthetic Lethal Approach to Target MYC-Driven Cancers,” Cancer Research 82 (2022): 969–971.

[73] J. Zhang, X. Liu, P. Hou, et al., “BRCA1 Orchestrates the Response to BI-2536 and Its Combination With Alisertib in MYC-Driven Small Cell Lung Cancer,” Cell Death & Disease 15, no. 7 (2024): 551.

[74] P. Lorenc, A. Sikorska, S. Molenda, N. Guzniczak, H. Dams-Kozlowska, and A. Florczak, “Physiological and Tumor-Associated Angiogenesis: Key Factors and Therapy Targeting VEGF/VEGFR Pathway,” Biomedicine & Pharmacotherapy 180 (2024): 117585.

[75] J. Mou, C. Li, Q. Zheng, X. Meng, and H. Tang, “Research Progress in Tumor Angiogenesis and Drug Resistance in Breast Cancer,” Cancer Biology & Medicine 21, no. 7 (2024): 571–585.

[76] M. Adiamah, B. Poole, J. C. Lindsey, et al., “MYC-Dependent Upregulation of the De Novo Serine and Glycine Synthesis Pathway Is a Targetable Metabolic Vulnerability in Group 3 Medulloblastoma,” Neuro-Oncology 27 (2025): 237–253.

[77] N. Stepien, D. Senfter, J. Furtner, et al., “Proof-Of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR,” Cancers 15 (2023): 2525.

[78] X. Chen, Z. Q. Guo, D. Cao, Y. Chen, and J. Chen, “Retraction Note: MYC-Mediated Upregulation of PNO1 Promotes Glioma Tumorigenesis by Activating THBS1/FAK/Akt Signaling,” Cell Death & Disease 15, no. 6 (2024): 461.

[79] A. W. Tan, X. Tong, S. Alvarez-Cubela, et al., “c-MYC Drives Inflammation of the Maternal-Fetal Interface, and Neonatal Lung Remodeling Induced by Intra-Amniotic Inflammation,” Frontiers in Cell and Developmental Biology 11 (2023): 1245747.

[80] R. Hou, Y. Yu, M. N. Sluter, et al., “Targeting EP2 Receptor With Multifaceted Mechanisms for High-Risk Neuroblastoma,” Cell Reports 39, no. 12 (2022): 111000.

[81] J. Saqib, B. Park, Y. Jin, J. Seo, J. Mo, and J. Kim, “Identification of Niche-Specific Gene Signatures Between Malignant Tumor Microenvironments by Integrating Single Cell and Spatial Transcriptomics Data,” Genes 14 (2023): 2033.

[82] M. D. Shields, K. G. Minton, H. Ozakinci, et al., “ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin,” Molecular Cancer Therapeutics ahead of print, January 26, 2026,

[83] R. Dhanasekaran, A. S. Hansen, J. Park, et al., “MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible Through Restoration of Proinflammatory Macrophages,” Cancer Research 83 (2023): 626–640.

[84] J. V. Lee, F. Housley, C. Yau, et al., “Author Correction: Combinatorial Immunotherapies Overcome MYC-Driven Immune Evasion in Triple Negative Breast Cancer,” Nature Communications 13 (2022): 7140.

[85] K. M. Lee, C. C. Lin, A. Servetto, et al., “Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer,” Cancer Immunology Research 10 (2022): 829–843.

[86] Y. Wu, Z. Yi, J. Li, et al., “FGFR Blockade Boosts T Cell Infiltration Into Triple-Negative Breast Cancer by Regulating Cancer-Associated Fibroblasts,” Theranostics 12, no. 10 (2022): 4564–4580.

[87] M. Reck, D. P. Baird, S. Veizades, et al., “Multiomic Analysis of Human Kidney Disease Identifies a Tractable Inflammatory and Pro-Fibrotic Tubular Cell Phenotype,” Nature Communications 16, no. 1 (2025): 4745.

[88] R. Melchionna, P. Trono, C. A. Di, F. Di Modugno, and P. Nisticò, “Transcription Factors in Fibroblast Plasticity and CAF Heterogeneity,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 347.

[89] K. Raaijmakers, G. J. Adema, J. Bussink, and M. Ansems, “Cancer-Associated Fibroblasts, Tumor and Radiotherapy: Interactions in the Tumor Micro-Environment,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 323.

[90] Q. Qin, R. Yu, J. E. Eriksson, H. I. Tsai, and H. Zhu, “Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Therapy: Challenges and Opportunities,” Cancer Letters 591 (2024): 216859.

[91] D. Hu, Z. Li, B. Zheng, et al., “Cancer-Associated Fibroblasts in Breast Cancer: Challenges and Opportunities,” Cancer Communications 42, no. 5 (2022): 401–434.

[92] H. Jia, X. Chen, L. Zhang, and M. Chen, “Cancer Associated Fibroblasts in Cancer Development and Therapy,” Journal of Hematology & Oncology 18, no. 1 (2025): 36.

[93] F. Zhang, Y. Ma, D. Li, et al., “Cancer Associated Fibroblasts and Metabolic Reprogramming: Unraveling the Intricate Crosstalk in Tumor Evolution,” Journal of Hematology & Oncology 17, no. 1 (2024): 80.

[94] Y. Gu and C. A. Benavente, “Landscape and Treatment Options of Shapeshifting Small Cell Lung Cancer,” Journal of Clinical Medicine 13 (2024): 3120.

[95] F. Y. Gao, X. T. Li, K. Xu, R. T. Wang, and X. X. Guan, “c-MYC Mediates the Crosstalk Between Breast Cancer Cells and Tumor Microenvironment,” Cell Communication and Signaling 21, no. 1 (2023): 28.

[96] F. L. G. Yang and Y. Fan, “Navigating Tumor Angiogenesis: Therapeutic Perspectives and Myeloid Cell Regulation Mechanism,” Angiogenesis 27 (2024): 333–349.

[97] F. Xiao, H. Zhu, Y. Xiong, et al., “Positive Feedback Loop of c-MYC/XTP6/NDH2/NF-κB to Promote Malignant Progression in Glioblastoma,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 187.

[98] X. Y. Qin, Y. Xu, H. Mishra, et al., “Oncogenic Function and Transcriptional Dynamics of MYCN in Liver Tumorigenesis,” PNAS 123, no. 8 (2026): e2521923123.

[99] Y. Wang, Z. Wang, X. Wu, et al., “Paeonol Promotes Reendothelialization After Vascular Injury Through Activation of C-MYC/VEGFR2 Signaling Pathway,” Drug Design Development and Therapy 17 (2023): 1567–1582.

[100] I. Tuleta, A. Hanna, C. Humeres, et al., “Fibroblast-Specific TGF-β Signaling Mediates Cardiac Dysfunction, Fibrosis, and Hypertrophy in Obese Diabetic Mice,” Cardiovascular Research 120, no. 16 (2024): 2047–2063.

[101] G. Cognet and A. Muir, “Identifying Metabolic Limitations in the Tumor Microenvironment,” Science Advances 10 (2024): eadq7305.

[102] Y. Chang, N. Wang, S. Li, et al., “SLC3A2-Mediated Lysine Uptake by Cancer Cells Restricts T-Cell Activity in Hepatocellular Carcinoma,” Cancer Research 85, no. 12 (2025): 2250–2267.

[103] R. M. Hazem, R. F. Aboslema, E. T. Mehanna, S. M. Kishk, M. Elsayed, and N. M. El-Sayed, “Antitumor Effect of Trimetazidine in a Model of Solid Ehrlich Carcinoma Is Mediated by Inhibition of Glycolytic Pathway and AKT Signaling,” Chemico-Biological Interactions 383 (2023): 110672.

[104] Y. An, J. Zhou, L. Su, et al., “Clinicopathologic, Genetic and Immune Cell Infiltration Analysis of Colorectal Signet Ring Cell Carcinoma With Comparison to Conventional Adenocarcinoma,” Journal of the National Cancer Center 6, no. 1 (2026): 30–39.

[105] X. Liu, J. Wang, L. J. Wu, B. Trinh, and R. Y. L. Tsai, “IMPDH Inhibition Decreases TERT Expression and Synergizes the Cytotoxic Effect of Chemotherapeutic Agents in Glioblastoma Cells,” International Journal of Molecular Sciences 25, no. 11 (2024): 5992.

[106] L. Jiao, Y. Liu, X. Y. Yu, et al., “Ribosome Biogenesis in Disease: New Players and Therapeutic Targets,” Signal Transduction and Target Therapy 8, no. 1 (2023): 15.

[107] H. Jia and M. Chen, “Cancer Associated Fibroblasts in Cancer Development and Therapy,” Journal of Hematology & Oncology 18 (2025): 36.

[108] C. Pulito, S. Vaccarella, A. C. Palcau, et al., “MicroRNA-Mediated PTEN Downregulation as a Novel Non-Genetic Mechanism of Acquired Resistance to PI3Kα Inhibitors of Head & Neck Squamous Cell Carcinoma,” Drug Resistance Updates 81 (2025): 101251.

[109] K. Liao, P. Chen, M. Zhang, et al., “Critical Roles of the miR-17∼92 Family in Thymocyte Development, Leukemogenesis, and Autoimmunity,” Cell Reports 43, no. 6 (2024): 114261.

[110] H. Shen, F. Ye, D. Xu, L. Fang, X. Zhang, and J. Zhu, “The MYEOV-MYC Association Promotes Oncogenic miR-17/93-5p Expression in Pancreatic Ductal Adenocarcinoma,” Cell Death & Disease 13, no. 1 (2021): 15.

[111] I. Sturmlechner, C. Zhang, C. C. Sine, et al., “p21 Produces a Bioactive Secretome That Places Stressed Cells Under Immunosurveillance,” Science 374, no. 6567 (2021): eabb3420.

[112] K. Engeland, “Cell Cycle Regulation: P53-p21-RB Signaling,” Cell Death and Differentiation 29, no. 5 (2022): 946–960.

[113] Q. Tang, K. Tang, G. R. Markby, et al., “Autophagy Regulates Cellular Senescence by Mediating the Degradation of CDKN1A/p21 and CDKN2A/p16 Through SQSTM1/p62-Mediated Selective Autophagy in Myxomatous Mitral Valve Degeneration,” Autophagy 21, no. 7 (2025): 1433–1455.

[114] K. Tanaka, H. A. Yu, S. Yang, et al., “Targeting Aurora B Kinase Prevents and Overcomes Resistance to EGFR Inhibitors in Lung Cancer by Enhancing BIM- and PUMA-Mediated Apoptosis,” Cancer Cell 39, no. 9 (2021): 1245–1261.e6.

[115] J. Fevereiro, A. G. Fraga, C. Capela, et al., “Genetic Variants in Human BCL2L11 (BIM) Are Associated With Ulcerative Forms of Buruli Ulcer,” Emerging Microbes & Infections 10, no. 1 (2021): 223–225.

[116] O. S. Shah, A. Nasrazadani, J. Foldi, et al., “Spatial Molecular Profiling of Mixed Invasive Ductal and Lobular Breast Cancers Reveals Heterogeneity in Intrinsic Molecular Subtypes, Oncogenic Signatures, and Mutations,” PNAS 121, no. 31 (2024): e2322068121.

[117] R. L. Flaherty, F. Hughes, G. Sflomos, et al., “LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma,” Cancer Research 86, no. 10 (2026): 2487–2507.

[118] S. G. Yang, X. W. Wang, C. Qian, and F. Q. Zhou, “Reprogramming Neurons for Regeneration: The Fountain of Youth,” Progress in Neurobiology 214 (2022): 102284.

[119] J. Jiang and Y. Yu, “Eflornithine for Treatment of High-Risk Neuroblastoma,” Trends in Pharmacological Sciences 45, no. 6 (2024): 577–578.

[120] N. Desi, V. Teh, Q. Y. Tong, et al., “MiR-138 Is a Potent Regulator of the Heterogenous MYC Transcript Population in Cancers,” Oncogene 41, no. 8 (2022): 1178–1189.

[121] C. Fieni, C. Sorrentino, S. L. Ciummo, et al., “Immunoliposome-Based Targeted Delivery of the CRISPR/Cas9gRNA-IL30 Complex Inhibits Prostate Cancer and Prolongs Survival,” Experimental & Molecular Medicine 56, no. 9 (2024): 2033–2051.

[122] B. Freie, A. H. Ibrahim, P. A. Carroll, et al., “MAX Inactivation Deregulates the MYC Network and Induces Neuroendocrine Neoplasia in Multiple Tissues,” Science Advances 11, no. 17 (2025): eadt3177.

[123] A. S. Ireland, D. A. Xie, S. B. Hawgood, et al., “Basal Cell of Origin Resolves Neuroendocrine-Tuft Lineage Plasticity in Cancer,” Nature 647, no. 8088 (2025): 257–267.

[124] T. Ramasamy, H. B. Ruttala, S. Munusamy, N. Chakraborty, and J. O. Kim, “Nano Drug Delivery Systems for Antisense Oligonucleotides (ASO) Therapeutics,” Journal of Controlled Release 352 (2022): 861–878.

[125] L. Torres-Masjoan, S. Aguti, H. Zhou, and F. Muntoni, “Clinical Applications of Exon-Skipping Antisense Oligonucleotides in Neuromuscular Diseases,” Molecular Therapy 33, no. 6 (2025): 2689–2704.

[126] M. Dinevska, S. S. Widodo, L. Furst, et al., “Cell Signaling Activation and Extracellular Matrix Remodeling Underpin Glioma Tumor Microenvironment Heterogeneity and Organization,” Cellular Oncology 46 (2023): 589–602.

[127] Z. Huang and C. Huang, “Epithelial-Mesenchymal Transition: The History, Regulatory Mechanism, and Cancer Therapeutic Opportunities,” MedComm 3 (2022): e144.

[128] K. L. Hung, K. E. Yost, L. Xie, et al., “ecDNA Hubs Drive Cooperative Intermolecular Oncogene Expression,” Nature 600, no. 7890 (2021): 731–736.

[129] A. C. Palcau, V. Canu, S. Donzelli, S. Strano, C. Pulito, and G. Blandino, “CircPVT1: A Pivotal Circular Node Intersecting Long Non-Coding-PVT1 and c-MYC Oncogenic Signals,” Molecular Cancer 21, no. 1 (2022): 33.

[130] F. Gao, X.-T. Li, K. Xu, R.-T. Wang, and X. X. Guan, “C-MYC Mediates the Crosstalk Between Breast Cancer Cells and Tumor Microenvironment,” Cell Communication and Signaling 21 (2023): 28.

[131] Z. Fang, Q. Meng, J. Xu, et al., “Signaling Pathways in Cancer-Associated Fibroblasts: Recent Advances and Future Perspectives,” Cancer Communications 43 (2023): 3–41.

[132] B. Du, Y. Zhang, P. Zhang, et al., “Joint Metabolomics and Transcriptomics Analysis Systematically Reveal the Impact of N-MYC in Neuroblastoma,” Scientific Reports 14 (2024): 20155.

[133] Y. Oshima, T. Haruki, S. Matsui, et al., “Clinical Significance of MYC Family Protein Expression in Surgically Resected High-Grade Neuroendocrine Carcinoma of the Lung,” Thoracic Cancer 14 (2023): 758–765.

[134] M. Winkle, M. M. Tayari, K. Kok, et al., “The LncRNA KTN1-AS1 Co-Regulates a Variety of Myc-Target Genes and Enhances Proliferation of Burkitt Lymphoma Cells,” Human Molecular Genetics 31 (2022): 4193–4206.

[135] Z. Zhang, F. Li, X. Dai, et al., “The Long Non-Coding RNA UGDH-AS1 Encodes an NK-Cell-Inhibiting Micropeptide in Triple-Negative Breast Cancers,” Nature Communications 16, no. 1 (2025): 11434.

[136] K. Yang, W. Zhang, L. Zhong, et al., “Long Non-Coding RNA HIF1A-As2 and MYC Form a Double-Positive Feedback Loop to Promote Cell Proliferation and Metastasis in KRAS-Driven Non-Small Cell Lung Cancer,” Cell Death and Differentiation 30, no. 6 (2023): 1533–1549.

[137] G. A. García, A. M. Ferrer, P. G. Vallejo, et al., “Targeting ELOVL6 to Disrupt c-MYC Driven Lipid Metabolism in Pancreatic Cancer Enhances Chemosensitivity,” Nature Communications 16, no. 1 (2025): 1694.

[138] D. Kazmierczak, K. Jopek, K. Sterzynska, M. Nowicki, M. Rucinski, and R. Januchowski, “The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines,” International Journal of Molecular Sciences 23, no. 1 (2022): 526.

[139] A. C. Palcau, C. Pulito, V. De Pascale, et al., “CircPVT1 Weakens miR-33a-5p Unleashing the c-MYC/GLS1 Metabolic Axis in Breast Cancer,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 100.

[140] F. Yan, V. Jiang, and A. Jordan, “The HSP90-MYC-CDK9 Network Drives Therapeutic Resistance in Mantle Cell Lymphoma,” Experimental Hematology & Oncology 13, no. 1 (2024): 14.

[141] Y. See and M. J. Fullwood, “MYC Overexpression Leads to Increased Chromatin Interactions at Super-Enhancers and MYC Binding Sites,” Genome Research 32 (2022): 629–642.

[142] W. Zuo, W. Huang, H. Chen, Y. Xu, and Y. Zhang, “A Novel Protein Encoded by circIMP3 Promotes Prostate Cancer Progression by Regulating Alternative Splicing and Tumor Microenvironment,” Frontiers in Cell and Developmental Biology 13 (2025): 1722674.

[143] S. Wei and C. Y. Zhang, “Target-Initiated Cascade Signal Amplification Lights up a G-Quadruplex for a Label-Free Detection of Circular Ribonucleic Acids,” Analytical Chemistry 94 (2022): 9193–9200.

[144] Y. Tang, F. Yuan, M. Cao, et al., “CircRNA-mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c-MYC Axis,” Advanced Science 12, no. 20 (2025): e2410591.

[145] Z. Lei, Z. Zhu, Z. Yao, et al., “Reciprocal Interactions Between LncRNAs and MYC in Colorectal Cancer: Partners in Crime,” Cell Death & Disease 15, no. 7 (2024): 539.

[146] Y. Luo, S. Yang, X. Wu, et al., “Intestinal MYC Modulates Obesity-Related Metabolic Dysfunction,” Nature Metabolism 3, no. 7 (2021): 923–939.

[147] Z. Jing, Q. Liu, X. He, et al., “NCAPD3 Enhances Warburg Effect Through c-MYC and E2F1 and Promotes the Occurrence and Progression of Colorectal Cancer,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 198.

[148] X. Wang, C. Jiang, and Q. Li, “Serinc2 Drives the Progression of Cervical Cancer Through Regulating Myc Pathway,” Cancer Medicine 13, no. 19 (2024): e70296.

[149] M. L. Amaya, A. Inguva, S. Pei, et al., “The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation,” Blood 139, no. 4 (2022): 584–596.

[150] Q. Pan, F. Yu, H. Jin, et al., “eIF3f Mediates SGOC Pathway Reprogramming by Enhancing Deubiquitinating Activity in Colorectal Cancer,” Advanced Science 10, no. 27 (2023): e2300759.

[151] T. Haykal, R. Yang, C. Tohme, et al., “Surgery-Induced Neutrophil Extracellular Traps Promote Tumor Metastasis by Reprogramming Cancer Cell Lipid Metabolism,” Cancer Research 85, no. 24 (2025): 4995–5014.

[152] Z. Hu, W. Xu, H. Wang, et al., “CARM1-Induced LncRNA NEAT1 Synchronously Activates N-MYC and GalNAcT-I to Accelerate the Progression of Neuroblastoma,” Gene 938 (2025): 149164.

[153] M. Rahmat, K. Clement, J. B. Alberge, et al., “Selective Enhancer Gain-Of-Function Deregulates MYC Expression in Multiple Myeloma,” Cancer Research 84, no. 24 (2024): 4173–4183.

[154] Y. Zhang, M. A. Urquijo, R. G. Zitnay, et al., “A BRN2:MYC Transcriptional Axis Regulates Interconversion Between Therapy-Resistant and Tumorigenic Phenotypes in Melanoma,” Cell Reports 44, no. 12 (2025): 116675.

[155] A. W. T. Steffeck, A. A. Cordova, and S. A. Abdulkadir, “MAX in Cancer: Dynamic Role of MYC's Partner-In-Crime,” Trends in Cancer 12, no. 3 (2026): 217–220.

[156] A. Q. Khaleel, S. A. Jasim, S. V. Menon, et al., “siRNA-Based Knockdown of LncRNAs: A New Modality to Target Tumor Progression,” Pathology, Research and Practice 266 (2025): 155746.

[157] S. T. Jakobsen, R. A. M. Jensen, M. S. Madsen, et al., “MYC Activity at Enhancers Drives Prognostic Transcriptional Programs Through an Epigenetic Switch,” Nature Genetics 56, no. 4 (2024): 663–674.

[158] K. Fujinaga, F. Huang, and B. M. Peterlin, “P-TEFb: The Master Regulator of Transcription Elongation,” Molecular Cell 83, no. 3 (2023): 393–403.

[159] M. Welcker, B. Wang, D. V. Rusnac, et al., “Two Diphosphorylated Degrons Control C-MYC Degradation by the Fbw7 Tumor Suppressor,” Science Advances 8 (2022): eabl7872.

[160] P. Trzaskoma, S. Jung, A. Pękowska, et al., “3D Chromatin Architecture, BRD4, and Mediator Have Distinct Roles in Regulating Genome-Wide Transcriptional Bursting and Gene Network,” Science Advances 10, no. 32 (2024): eadl4893.

[161] G. Xie, A. Zhu, and X. Gu, “Converged DNA Damage Response Renders Human Hepatocellular Carcinoma Sensitive to CDK7 Inhibition,” Cancers 14, no. 7 (2022): 1714.

[162] J. Cazarin, R. E. DeRollo, S. Shahidan, et al., “MYC Disrupts Transcriptional and Metabolic Circadian Oscillations in Cancer and Promotes Enhanced Biosynthesis,” PLoS Genetics 19 (2023): e1010904.

[163] F. Giuntini, Í. González-Larreategui, A. Herencia-Ropero, et al., “MYC Inhibition by Omomyc Causes DNA Damage and Overcomes PARPi Resistance in Breast Cancer,” Cell Reports 44, no. 12 (2025): 116604.

[164] J. Lin, X. Wang, S. Zhai, et al., “Hypoxia-Induced Exosomal circPDK1 Promotes Pancreatic Cancer Glycolysis via C-MYC Activation by Modulating miR-628-3p/BPTF Axis and Degrading BIN1,” Journal of Hematology & Oncology 15 (2022): 128.

[165] C. Shembrey, R. Yang, J. Casan, et al., “Principles of CRISPR-Cas13 Mismatch Intolerance Enable Selective Silencing of Point-Mutated Oncogenic RNA With Single-Base Precision,” Science Advances 10 (2024): eadl0731.

[166] Y. Yin, Y. Sun, H. Yao, et al., “TMEM105 Modulates Disulfidptosis and Tumor Growth in Pancreatic Cancer via the β-Catenin-c-MYC-GLUT1 Axis,” International Journal of Biological Sciences 21, no. 5 (2025): 1932–1948.

[167] S. Suo, D. Zhao, F. Li, et al., “Homoharringtonine Inhibits the NOTCH/MYC Pathway and Exhibits Antitumor Effects in T-Cell Acute Lymphoblastic Leukemia,” Blood 144, no. 12 (2024): 1343–1347.

[168] M. Masood, Q. Ding, A. D. Cawte, et al., “Genetic Screening for Anticancer Genes Highlights FBLN5 as a Synthetic Lethal Partner of MYC,” Cell Communication and Signaling 21, no. 1 (2023): 295.

[169] S. Schutz, C. Bergsdorf, B. Goretzki, et al., “The Disordered MAX N-Terminus Modulates DNA Binding of the Transcription Factor MYC:MAX,” Journal of Molecular Biology 434 (2022): 167833.

[170] J. Ma, L. Li, B. Ma, et al., “MYC Induces CDK4/6 Inhibitors Resistance by Promoting pRB1 Degradation,” Nature Communications 15, no. 1 (2024): 1871.

[171] H. Luo, Q. Li, J. Hong, et al., “Targeting TNF/IL-17/MAPK Pathway in hE2A-PBX1 Leukemia: Effects of OUL35, KJ-Pyr-9, and CID44216842,” Haematologica 109, no. 7 (2024): 2092–2110.

[172] A. Singh, A. Kumar, P. Kumar, et al., “A Novel Inhibitor L755507 Efficiently Blocks c-MYC-MAX Heterodimerization and Induces Apoptosis in Cancer Cells,” Journal of Biological Chemistry 297, no. 1 (2021): 100903.

[173] A. K. Esser, M. H. Ross, F. Fontana, et al., “Nanotherapy Delivery of c-MYC Inhibitor Targets Protumor Macrophages and Preserves Antitumor Macrophages in Breast Cancer,” Theranostics 10, no. 17 (2020): 7510–7526.

[174] J. Li, Q. Zhang, P. Zhao, et al., “Targeting Aldose Reductase in Pulmonary Fibrosis: Blocking De Novo Fatty Acid Synthesis Halts Pro-Fibrotic M2 Polarization,” International Journal of Biological Macromolecules 337, pt. 2 (2026): 149590.

[175] Y. Zhao, Y. Wang, W. Chen, et al., “Targeted Intervention of eIF4A1 Inhibits EMT and Metastasis of Pancreatic Cancer Cells via c-MYC/miR-9 Signaling,” Cancer Cell International 21, no. 1 (2021): 670.

[176] Y. Lu, Y. Lin, X. Zhang, et al., “LncRNA-AP006284.1 Promotes Prostate Cancer Cell Growth and Motility by Forming RNA-DNA Triplexes and Recruiting GNL3/SFPQ Complex to Facilitate RASSF7 Transcription,” Genes & Diseases 10, no. 2 (2023): 317–320.

[177] E. Garralda, M. E. Beaulieu, V. Moreno, et al., “MYC Targeting by OMO-103 in Solid Tumors: A Phase 1 Trial,” Nature Medicine 30, no. 3 (2024): 762–771.

[178] C. P. Chang, T. K. Yeh, C. T. Chen, et al., “Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination With Everolimus,” Molecular Cancer Therapeutics 23, no. 6 (2024): 766–779.

[179] F. Faienza, F. Polverino, G. Rajendraprasad, et al., “AMBRA1 Phosphorylation by CDK1 and PLK1 Regulates Mitotic Spindle Orientation,” Cellular and Molecular Life Sciences 80, no. 9 (2023): 251.

[180] D. Wang, B. Veo, A. Pierce, et al., “A Novel PLK1 Inhibitor Onvansertib Effectively Sensitizes MYC-Driven Medulloblastoma to Radiotherapy,” Neuro-Oncology 24, no. 3 (2022): 414–426.

[181] Y. Wang, M. Yao, C. Li, et al., “Targeting ST8SIA6-AS1 Counteracts KRAS(G12C) Inhibitor Resistance Through Abolishing the Reciprocal Activation of PLK1/c-MYC Signaling,” Experimental Hematology & Oncology 12, no. 1 (2023): 105.

[182] C. Zhao, F. Zhao, L. Yang, et al., “Directly Suppressing MYC Function With Novel Alkynyl-Substituted Phenylpyrazole Derivatives That Induce Protein Degradation and Perturb MYC/MAX Interaction,” Journal of Medicinal Chemistry 67, no. 14 (2024): 11751–11768.

[183] L. C. Lustig, D. Dingar, W. B. Tu, et al., “Inhibiting MYC Binding to the E-Box DNA Motif by ME47 Decreases Tumour Xenograft Growth,” Oncogene 36, no. 49 (2017): 6830–6837.

[184] M. Tang, J. Crown, and M. J. Duffy, “Targeting MYC for the Treatment of Breast Cancer: Use of the Novel MYC-GSPT1 Degrader, GT19630,” Investigational New Drugs 43, no. 1 (2025): 167–179.

[185] K. C. Jeong, K. T. Kim, H. H. Seo, et al., “Intravesical Instillation of c-MYC Inhibitor KSI-3716 Suppresses Orthotopic Bladder Tumor Growth,” Journal D urologie 191, no. 2 (2014): 510–518.

[186] Y. C. Koh, Y. W. Tsai, P. S. Lee, K. Nagabhushanam, C. T. Ho, and M. H. Pan, “Amination Potentially Augments the Ameliorative Effect of Curcumin on Inhibition of the IL-6/Stat3/c-MYC Pathway and Gut Microbial Modulation in Colitis-Associated Tumorigenesis,” Journal of Agricultural and Food Chemistry 70, no. 46 (2022): 14744–14754.

[187] M. H. Hu, Y. Q. Wang, Z. Y. Yu, et al., “Correction to “Discovery of a New Four-Leaf Clover-Like Ligand as a Potent c-MYC Transcription Inhibitor Specifically Targeting the Promoter G-Quadruplex”,” Journal of Medicinal Chemistry 69 (2026): 14989.

[188] T. Y. Wu, X. C. Chen, G. X. Tang, et al., “Development and Characterization of Benzoselenazole Derivatives as Potent and Selective c-MYC Transcription Inhibitors,” Journal of Medicinal Chemistry 66, no. 8 (2023): 5484–5499.

[189] M. H. Hu, T. Y. Wu, Q. Huang, and G. Jin, “New Substituted Quinoxalines Inhibit Triple-Negative Breast Cancer by Specifically Downregulating the c-MYC Transcription,” Nucleic Acids Research 47, no. 20 (2019): 10529–10542.

[190] S. Cao, Q. Su, Y. H. Chen, et al., “Molecular Insights Into the Specific Targeting of c-MYC G-Quadruplex by Thiazole Peptides,” International Journal of Molecular Sciences 25, no. 1 (2024): 623.

[191] T. J. Hagenbeek, J. R. Zbieg, M. Hafner, et al., “An Allosteric Pan-TEAD Inhibitor Blocks Oncogenic YAP/TAZ Signaling and Overcomes KRAS G12C Inhibitor Resistance,” Nature Cancer 4, no. 6 (2023): 812–828.

[192] T. Zhu, H. Li, S. Mao, et al., “Endogenous YAP/TAZ Partitioning in TEAD Condensates Orchestrates the Hippo Response,” Molecular Cell 85, no. 18 (2025): 3425–3442.e10.

[193] K. Sato, F. Faraji, R. D. Cervantes-Villagrana, et al., “Targeting YAP/TAZ-TEAD Signaling as a Therapeutic Approach in Head and Neck Squamous Cell Carcinoma,” Cancer Letters 612 (2025): 217467.

[194] S. Peuget and G. Selivanova, “MDM2-PROTAC Versus MDM2 Inhibitors: Beyond p53 Reactivation,” Cancer Discovery 13, no. 5 (2023): 1043–1045.

[195] Y. Huang, X. Che, P. W. Wang, and X. Qu, “p53/MDM2 Signaling Pathway in Aging, Senescence and Tumorigenesis,” Seminars in Cancer Biology 101 (2024): 44–57.

[196] T. Brummer and R. Zeiser, “The Role of the MDM2/p53 Axis in Antitumor Immune Responses,” Blood 143, no. 26 (2024): 2701–2709.

[197] C. M. Adams, R. Mitra, Y. Xiao, et al., “Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer,” Cancer Discovery 13, no. 5 (2023): 1210–1229.

[198] J. Dilly, M. T. Hoffman, L. Abbassi, et al., “Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer,” Cancer Discovery 14, no. 11 (2024): 2135–2161.

[199] Z. Sabeel, J. Wang, J. Dong, Y. Liu, C. Yu, and Z. Yang, “The Duality of GSK-3β in Urinary Bladder Cancer: Tumor Suppressor and Promoter Roles Through Multiple Signaling Pathways,” Biochimica et Biophysica Acta – Reviews on Cancer 1880, no. 3 (2025): 189324.

[200] D. Wang, S. Wu, J. He, et al., “FAT4 Overexpression Promotes Antitumor Immunity by Regulating the β-Catenin/STT3/PD-L1 Axis in Cervical Cancer,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 222.

[201] Y. He, D. Liu, A. Ling, et al., “Inhibition of Wnt/β-Catenin Increases Anti-Tumor Activity by Synergizing With Sorafenib in Hepatocellular Carcinoma,” Cell Death & Disease 16, no. 1 (2025): 466.

[202] H. Zhu, Y. Gao, L. Liu, et al., “A Novel TNKS/USP25 Inhibitor Blocks the Wnt Pathway to Overcome Multi-Drug Resistance in TNKS-Overexpressing Colorectal Cancer,” Acta Pharmaceutica Sinica B 14, no. 1 (2024): 207–222.

[203] T. J. Dreyer, J. A. C. Keen, L. M. Wells, et al., “Porcupine Inhibition Is a Promising Pharmacological Treatment for Severe Sclerosteosis Pathologies,” Bone Resarch 13, no. 1 (2025): 44.

[204] O. S. Omer, A. Hertweck, L. B. Roberts, et al., “Cyclin-Dependent Kinase 9 as a Potential Target for Anti-TNF-Resistant Inflammatory Bowel Disease,” Cellular and Molecular Gastroenterology and Hepatology 14, no. 3 (2022): 625–641.

[205] X. P. Li, J. Qu, X. Q. Teng, et al., “The Emerging Role of Super-Enhancers as Therapeutic Targets in the Digestive System Tumors,” International Journal of Biological Sciences 19, no. 4 (2023): 1036–1048.

[206] H. Wang, S. Zhang, Y. Zhang, et al., “TAZ Is Indispensable for c-MYC-Induced Hepatocarcinogenesis,” Journal of Hepatology 76, no. 1 (2022): 123–134.

[207] X. Ren, Z. Rong, X. Liu, et al., “The Protein Kinase Activity of NME7 Activates Wnt/β-Catenin Signaling to Promote One-Carbon Metabolism in Hepatocellular Carcinoma,” Cancer Research 82, no. 1 (2022): 60–74.

[208] V. Shah, G. Giotopoulos, H. Osaki, et al., “Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs via p300 Coactivation,” Blood 145, no. 7 (2025): 748–764.

[209] Q. Wan, L. Zhu, C. Chen, et al., “PIM1 Attenuates Innate Immunity to Foster Coronavirus Replication Through Ubiquitin Ligase β-TrCP-Mediated IFNAR1 Degradation,” Advanced Science 12, no. 37 (2025): e03487.

[210] D. H. Oh, X. Ma, S. J. Hogg, et al., “Rationally Designed Chimeric PI3K-BET Bromodomain Inhibitors Elicit Curative Responses in MYC-Driven Lymphoma,” PNAS 120, no. 36 (2023): e2306414120.

[211] S. Bibbò, E. Capone, G. Lovato, et al., “EV20/Omomyc: A Novel Dual MYC/HER3 Targeting Immunoconjugate,” Journal of Controlled Release 374 (2024): 171–180.

[212] P. E. Thompson and J. Shortt, “Defeating MYC With Drug Combinations or Dual-Targeting Drugs,” Trends in Pharmacological Sciences 45 (2024): 490–502.

[213] T. F. Cyberski, A. Singh, M. Korzinkin, et al., “Acquired Resistance to Immunotherapy and Chemoradiation in MYC Amplified Head and Neck Cancer,” NPJ Precision Oncology 8 (2024): 114.

[214] S. Song, L. Huang, X. Zhou, and J. Yu, “Exploring the Toxicological Network in Diabetic Microvascular Disease,” International Journal of Surgery 111, no. 6 (2025): 3895–3907.

[215] M. Li, J. Yu, and L. Ju, “USP43 Stabilizes c-MYC to Promote Glycolysis and Metastasis in Bladder Cancer,” Cell Death & Disease 15, no. 1 (2024): 44.

[216] X. Y. Wang, Y. Wei, B. Hu, et al., “c-MYC-Driven Glycolysis Polarizes Functional Regulatory B Cells That Trigger Pathogenic Inflammatory Responses,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 105.

[217] J. Yu, J. Han, M. Yu, H. Rui, A. Sun, and H. Li, “EZH2 Inhibition Sensitizes MYC-High Medulloblastoma Cancers to PARP Inhibition by Regulating NUPR1-Mediated DNA Repair,” Oncogene 44, no. 6 (2025): 391–405.

[218] H. Kotani, H. Oshima, J. C. Boucher, et al., “Dual Inhibition of SUMOylation and MEK Conquers MYC-Expressing KRAS-Mutant Cancers by Accumulating DNA Damage,” Journal of Biomedical Science 31, no. 1 (2024): 68.

[219] M. G. Formelli, A. Palloni, S. Tavolari, et al., “Classic Versus Innovative Strategies for Immuno-Therapy in Pancreatic Cancer,” Advanced Drug Delivery Reviews 225 (2025): 115671.

[220] W. Zhao, X. Wang, L. Han, et al., “SLC13A3 Is a Major Effector Downstream of Activated β-Catenin in Liver Cancer Pathogenesis,” Nature Communications 15, no. 1 (2024): 7522.

[221] X. Shi, Y. Cen, L. Shan, et al., “N-Myc Downstream Regulated Gene 1 Suppresses Osteoblast Differentiation Through Inactivating Wnt/β-Catenin Signaling,” Stem Cell Research & Therapy 13, no. 1 (2022): 53.

[222] Q. Li, S. Xia, X. Zhang, Y. Liu, X. Xiao, and J. Yang, “Gut Microbiota-Driven Pathways Linking Chronic Stress to Tumor Progression,” International Journal of Biological Sciences 22, no. 1 (2026): 258–279.

[223] Y. Shao, J. Wang, Y. Liu, et al., “Distinct Metabolomic and Proteomic Signatures in Parkinson's Disease Patients With REM Sleep Behavior Disorder,” Signal Transduction and Targeted Therapy 11, no. 1 (2026): 115.

[224] Í. González-Larreategui, M. Valdés-Bango Martín, S. Casacuberta-Serra, and L. Soucek, “MYC at the Tumor-Immune Interface: Mechanisms of Immune Escape and Immunotherapy Resistance,” Frontiers in Immunology 17 (2026): 1738440.

[225] Z. Wei, G. Gao, Q. He, L. Y. Kwok, and Z. Sun, “The Gut-Tumor Connection: The Role of Microbiota in Cancer Progression and Treatment Strategies,” Journal of Advanced Research 83 (2025): 489–507.

[226] H. Xu, H. Luo, J. Zhang, K. Li, and M. H. Lee, “Therapeutic Potential of Clostridium butyricum Anticancer Effects in Colorectal Cancer,” Gut Microbes 15, no. 1 (2023): 2186114.

[227] S. Li, Z. Wang, X. Wang, et al., “Integrative Characterization of MYC RNA-Binding Function,” Cell Genomics 5, no. 7 (2025): 100878.

[228] M. Vogt, S. N. Dudvarski, G. Y. Cruz, et al., “Targeting MYC Effector Functions in Pancreatic Cancer by Inhibiting the ATPase RUVBL1/2,” Gut 73, no. 9 (2024): 1509–1528.

[229] R. Tu, Z. Chen, Q. Bao, H. Liu, and G. Qing, “CROSSTALK Between Oncogenic MYC and Noncoding RNAs in Cancer,” Seminars in Cancer Biology 75 (2021): 62–71.

[230] J. K. Meena, J. H. Wang, N. J. Neill, et al., “MYC Induces Oncogenic Stress Through RNA Decay and Ribonucleotide Catabolism in Breast Cancer,” Cancer Discovery 14, no. 9 (2024): 1699–1716.

[231] J. Wang, Y. Yang, F. Shao, et al., “Acetate Reprogrammes Tumour Metabolism and Promotes PD-L1 Expression and Immune Evasion by Upregulating c-MYC,” Nature Metabolism 6, no. 5 (2024): 914–932.

[232] Y. Liu, J. Zhou, X. Li, et al., “tRNA-m(1)A Modification Promotes T Cell Expansion via Efficient MYC Protein Synthesis,” Nature Immunology 23, no. 10 (2022): 1433–1444.

[233] Y. Zhao, Y. R. Murciano-Goroff, J. Y. Xue, et al., “Diverse Alterations Associated With Resistance to KRAS(G12C) Inhibition,” Nature 599, no. 7886 (2021): 679–683.

[234] R. Dong, T. Wang, W. Dong, et al., “TGM2-Mediated Histone Serotonylation Promotes HCC Progression via MYC Signalling Pathway,” Journal of Hepatology 83, no. 1 (2025): 105–118.

[235] U. N. Wasko, J. Jiang, T. C. Dalton, et al., “Tumour-Selective Activity of RAS-GTP Inhibition in Pancreatic Cancer,” Nature 629, no. 8013 (2024): 927–936.

[236] O. A. Obisesan, S. Ofori, O. N. Orobator, H. Sharma, E. Groetecke, and S. G. Awuah, “Discovery of a Pyrazolopyridinone-Based MYC Inhibitor That Selectively Engages Intracellular c-MYC and Disrupts MYC-MAX Heterodimerization,” Journal of Medicinal Chemistry 68, no. 6 (2025): 6233–6251.

[237] Y. Xue, H. Jiang, T. Li, et al., “Inhibition of Tumor Growth Using a Conjugated Nanobody That Specifically Targets c-MYC,” Oncogene 44, no. 35 (2025): 3213–3224.

[238] A. G. Holmes, J. B. Parker, V. Sagar, et al., “A MYC Inhibitor Selectively Alters the MYC and MAX Cistromes and Modulates the Epigenomic Landscape to Regulate Target Gene Expression,” Science Advances 8, no. 17 (2022): eabh3635.

[239] L. S. Pongor, C. W. Schultz, L. Rinaldi, et al., “Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated With Worse Outcomes,” Cancer Discovery 13, no. 4 (2023): 928–949.

[240] J. Senapati, W. C. Fiskus, N. Daver, et al., “Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination With Azacitidine in Patients With Relapsed/Refractory Myeloid Malignancies,” Clinical Cancer Research 29, no. 21 (2023): 4352–4360.

[241] E. J. Vick, A. Hassan, K. Choi, et al., “Targeting of IRAK4 and GSPT1 Enhances Therapeutic Efficacy in AML via c-MYC Destabilization,” Leukemia 39, no. 9 (2025): 2163–2173.

[242] H. M. Lee, Z. Zheng, A. Sorokin, et al., “Reprogramming of Cellular Plasticity via ETS and MYC Core-Regulatory Circuits During Response to MAPK Inhibition in BRAF-Mutant Colorectal Cancer,” Clinical Cancer Research ahead of print, May 8, 2026, doi: http://doi.org/10.1158/1078-0432.CCR-25-4370.

[243] A. Daenthanasanmak, R. N. Bamford, M. Yoshioka, et al., “Triple Combination of BET Plus PI3K and NF-κB Inhibitors Exhibit Synergistic Activity in Adult T-Cell Leukemia/Lymphoma,” Blood Advances 6, no. 7 (2022): 2346–2360.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.